ANTI-MULLERIAN HORMONE AS A BIOMARKER FOR DETERMINING THE MORPHOLOGY OF POLYCYSTIC OVARIES
DOI:
https://doi.org/10.21856/j-PEP.2025.1.05Keywords:
anti-Mullerian hormone, polycystic ovary syndrome, phenotypic forms of polycystic ovary syndromeAbstract
Background. Polycystic ovary syndrome occurs in 13-18% of women of reproductive age and in 50% of women with menstrual disorders. In 50-75% of cases, it leads to the development of endocrine infertility.
The aim. To assess the clinical, diagnostic, and prognostic significance of anti-Mullerian hormone in patients with polycystic ovary syndrome.
Materials and methods. Retrospective cartographic analysis of 108 case histories of patients with polycystic ovary syndrome. Clinical data included determination of weight, height, body mass index, systolic and diastolic blood pressure. Laboratory data included determinations of anti-Mullerian hormone, testosterone, sex-binding globulin, bioavailable testosterone, free testosterone, dehydroepiandrostenedione sulfate, 17-hydroxyprogesterone, luteinizing hormone, follicle-stimulating hormone, prolactin, thyroid-stimulating hormone, glycated hemoglobin, total cholesterol, high-density lipoprotein, low-density lipoproteins and triglycerides.
Results. Anti-Mullerian hormone values were inversely correlated with age, weight, and body mass index values and directly with total testosterone, free testosterone, and bioavailable testosterone values. Women in the highest quartile (anti-Mullerian hormone: 19.5 ± 9.9 ng/mL; n=27) had a lower body mass index (29.5 ± 6.9 vs. 34.6 ± 10.6–36.8 ± 7.2 kg/m2), but higher total testosterone (52.3 ± 27.2 vs. 25.5 ± 10.4–35.2 ± 16.3 ng/dL), free testosterone (7.6 ± 6.0 vs. 4.5 ± 2.3–5.5 ± 3.2 ng/dL) and bioavailable testosterone (21.1 ± 17.0 vs. 12.3 ± 6.6–16.4 ± 8.7 ng/dL) compared to values in other quartiles.
Conclusions. The combination of high anti-Mullerian hormone and testosterone levels may indicate a reproductive subtype of polycystic ovary syndrome. Defining subtypes of polycystic ovary syndrome based on anti-Mullerian hormone may be a step towards understanding the heterogeneity of the syndrome and providing patient-centered care.
References
1. Karakas SE. Clin Chim Acta 2017;471: 248-253. https://doi.org/10.1016/j.cca.2017.06.009
2. Gimenez-Peralta I, Lilue M, et al. Front Endocrinol 2022;13: 915245. https://doi.org/10.3389/fendo.2022.915245.
3. Hoeger KM, Dokras, A, et al. J Clin Endocrinol Metab 2021;106(3): e1071-e1083. https://doi.org/10.1210/clinem/dgaa839.
4. Devillers MM, Petit F, et al. Med Sci 2019;35(3): 201-203. https://doi.org/10.1051/medsci/2019042
5. Roy S, Gandra D, еt al. Endocrinology 2018;159(9): 3433-3445. https://doi.org/10.1210/en.2018-00609
6. Sova H, Unkila-Kallio L, et al. Gynecol Endocrinol 2019;35(7): 595-600. https://doi.org/10.1080/09513590.2018.1559807
7. Carmina E, Lobo RA. Diagnostics 2022;12(10): 2555. https://doi.org/10.3390/diagnostics12102555
8. Teede H, Misso M, et al. Trends Endocrinol Metab 2019;30(7): 467-478. https://doi.org/10.1016/j.tem.2019.04.006.
9. Devillers MM, Petit F, et al. J Endocrinol 2019;240(2): 215-228. https://doi.org/10.1530/JOE-18-0313
10. Oldfield AL, Kazemi M, et al. J Clin Med 2021;10(14): 3192. https://doi.org/10.3390/jcm10143192
11. Simons P, Valkenburg O, et al. Endocrinol Diabetes Metab 2021;4(3): e00267. https://doi.org/10.1002/edm2.267
12. Dapas M, Dunaif A. Endocr Rev 2022;43(6): 927-965. https://doi.org/10.1210/endrev/bnac001
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Problems of Endocrine Pathology
This work is licensed under a Creative Commons Attribution 4.0 International License.
ISSN 
ISSN 
